A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

A Pilot, 4-Week, Randomized, Double-Blind, Placebo-Controlled, Inpatient, Multicenter Study of the Safety, Population Pharmacokinetics, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.

Study Overview

• Status: Completed
• Conditions: Schizophrenia
• Intervention / Treatment: Drug: Placebo; Drug: SP-624

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Garden Grove, California, United States, 92845
      • Collaborative Neuroscience Research
  • New Jersey
    • Marlton, New Jersey, United States, 08053
      • Hassman Research Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Is willing and able to provide written informed consent to participate in the study.
• Has an identified reliable informant.

• Is, in the investigator's opinion, suitable for initiating a washout from the subject's current antipsychotic regimen, if applicable, and is willing to abstain from prohibited psychotropic medications in accordance with study requirements.

  • Subjects must meet screening eligibility criteria and be in an inpatient setting prior to discontinuing antipsychotic medications.
  • Subject must be able, in the investigator's opinion, to safely discontinue prohibited psychotropic medications prior to Baseline without increased suicidality.
• Has a primary diagnosis of schizophrenia based on the Diagnostic and Statistical Manual 5th edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Psychotic Disorders Studies.
• Is experiencing an acute exacerbation or relapse of symptoms.
• Is in generally good physical health, in the investigator's opinion, based on Screening medical history, physical examination, vital signs, and clinical laboratory values.
• Has a body mass index (BMI) between 18 and 40 kg/m2, inclusive.
• For women of reproductive potential: has a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline.
• For women of reproductive potential and men with female partners of reproductive potential: agrees to remain abstinent from sexual intercourse or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug.

Key Exclusion Criteria:

• Is a woman who is pregnant, breastfeeding, or less than 6 months postpartum at Screening.
• Has any primary DSM-5 disorder other than schizophrenia, as confirmed by the MINI.
• Fails to discontinue prohibited psychotropic medications.
• Has, in the investigator's opinion, a significant risk of violent or destructive behavior.
• Is currently hospitalized involuntarily or incarcerated.
• Has a history or presence of any clinically significant medical condition, disease, or surgical history that could, in the investigator's opinion, jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug.
• Is, in the investigator's opinion, not a suitable candidate for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: SP-624; SP-624 oral capsule, 20 mg once daily	Drug: SP-624; Oral Capsule
PLACEBO_COMPARATOR: Placebo; Placebo oral capsule, once daily	Drug: Placebo; Oral Capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence of Adverse Events (AEs)	Up to 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Abnormal Clinical Laboratory Values	chemistry, hematology, and urinalysis tests will be performed	Up to 4 weeks
Change from Baseline in Blood Pressure (mmHg)	Blood pressure is measured by sphygmomanometer. Change from baseline measurement will be calculated	Up to 4 weeks
Change from Baseline in Pulse Rate (beats per minute)	Pulse rate is measured by sphygmomanometer. Change from baseline measurement will be calculated	Up to 4 weeks
Change from Baseline in Body Temperature (degrees celsius)	Body temperature is measured by oral thermometer. Change from baseline measurement will be calculated	Up to 4 weeks
Change from Baseline in Body Weight (kilograms)	Body weight is measured by weight scale. Measurement is reported in kilograms. Change from Baseline measurement will be calculated.	Up to 4 weeks
Change from Baseline in ECG Heart Rate (beats per minute)	Heart rate is measured by 12-lead electrocardiogram (ECG). Change from Baseline measure will be calculated.	Up to 4 weeks
Change from Baseline in ECG RR Interval (seconds)	RR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.	Up to 4 weeks
Change from Baseline in ECG PR Interval (milliseconds)	PR interval is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.	Up to 4 weeks
Change from Baseline in ECG QTcF Interval (milliseconds)	QTcF is measured by 12-lead electrocardiogram (ECG). Change from Baseline measurement will be calculated.	Up to 4 weeks
Number of Participants with Abnormal Physical Examination Findings		Up to 4 weeks
Number of Participants with treatment-emergent suicidal ideation or behavior	Treatment-emergent suicidal ideation and/or behavior will be assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) assessments	Up to 5 weeks
Number of Participants with treatment-emergent abnormal movements	Treatment-emergent abnormal movements will be assessed using a battery of movement assessments	Up to 4 weeks

Collaborators and Investigators

• Sponsor: Sirtsei Pharmaceuticals, Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 15, 2020
• Primary Completion (ACTUAL): April 15, 2021
• Study Completion (ACTUAL): April 15, 2021

Study Registration Dates

• First Submitted: July 27, 2020
• First Submitted That Met QC Criteria: August 10, 2020
• First Posted (ACTUAL): August 12, 2020

Study Record Updates

• Last Update Posted (ACTUAL): April 25, 2022
• Last Update Submitted That Met QC Criteria: April 18, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: SP-624-221

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No